Edition:
United States

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

30.55USD
23 Apr 2018
Change (% chg)

$-0.60 (-1.93%)
Prev Close
$31.15
Open
$31.00
Day's High
$31.10
Day's Low
$30.10
Volume
128,164
Avg. Vol
283,146
52-wk High
$32.60
52-wk Low
$12.70

Latest Key Developments (Source: Significant Developments)

Heron Therapeutics Announces Pricing Of Underwritten Public Offering
Wednesday, 28 Mar 2018 08:53pm EDT 

March 28 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC -‍ PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 6 MILLION SHARES OF ITS COMMON STOCK, OFFERED AT A PRICE OF $26.00 PER SHARE​.  Full Article

Heron Therapeutics Announces Proposed Public Offering Of Common Stock
Wednesday, 28 Mar 2018 04:14pm EDT 

March 28 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM UNDERWRITTEN OFFERING FOR COMMERCIAL LAUNCH OF HTX-011.HERON THERAPEUTICS INC - INTENDS TO OFFER AND SELL SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN REGISTERED PUBLIC OFFERING.  Full Article

Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials Of HTX-011 In Bunionectomy And Hernia Repair
Monday, 19 Mar 2018 08:00am EDT 

March 19 (Reuters) - Heron Therapeutics Inc ::HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR.HERON THERAPEUTICS INC - HTX-011 ACHIEVED ALL PRIMARY AND KEY SECONDARY ENDPOINTS.HERON THERAPEUTICS INC - SIGNIFICANTLY MORE PATIENTS RECEIVING HTX-011 WERE OPIOID-FREE THROUGH 72 HOURS AFTER SURGERY.HERON THERAPEUTICS INC - SIGNIFICANTLY FEWER HTX-011 PATIENTS EXPERIENCED SEVERE PAIN AT ANY TIME.HERON THERAPEUTICS INC - NDA FILING FOR HTX-011 TARGETED FOR H2 2018.  Full Article

Heron Therapeutics Qtrly Net Loss Per Share $1.09
Tuesday, 27 Feb 2018 04:15pm EST 

Feb 27 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS.QTRLY BASIC AND DILUTED NET LOSS PER SHARE $1.09.QTRLY NET PRODUCT SALES $10.1 MILLION VERSUS $1.3 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.79, REVENUE VIEW $9.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Heron Therapeutics Says Enrollment Complete In Both Pivotal Phase 3 Studies For Htx-011
Monday, 8 Jan 2018 08:30am EST 

Jan 8 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS - ENROLLMENT COMPLETE IN BOTH PIVOTAL PHASE 3 STUDIES FOR HTX-011; TOP-LINE RESULTS EXPECTED IN H1 OF 2018.HERON THERAPEUTICS INC - FOR PHASE 3 EFFICACY STUDIES IN BUNIONECTOMY AND HERNIA REPAIR, EXPECTS TO FILE AN NDA WITH FDA IN H2 OF 2018.  Full Article

Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock
Tuesday, 5 Dec 2017 09:00am EST 

Dec 5 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF SHARES OF ITS COMMON STOCK​.  Full Article

Heron Therapeutics Announces Public Offering Of Common Stock
Monday, 4 Dec 2017 04:01pm EST 

Dec 4 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - INTENDS TO USE PROCEEDS FROM PROPOSED SALE OF ITS SHARES OF COMMON STOCK FOR GENERAL CORPORATE PURPOSES.  Full Article

Heron Therapeutics gets FDA approval for Cinvanti
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Heron Therapeutics Inc :Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv).U.S. Commercial launch of Cinvanti is planned for January 2018​.Remain on-track with htx-011 which we expect to file for FDA review in 2018​.  Full Article

Heron Therapeutics reports qtrly diluted net loss per share $0.77
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Qtrly basic and diluted net loss per share $0.77‍​.Heron Therapeutics Inc - ‍net product sales of Sustol for three months ended September 30, 2017 were $8.6 million​.Heron Therapeutics Inc - ‍Heron's cash, cash equivalents and short-term investments were $74.0 million as of September 30, 2017​.Heron Therapeutics Inc - ‍guidance for full-year 2017 net product sales of Sustol remains $25 million to $30 million​.  Full Article

Heron Therapeutics granted FDA fast track designation for HTX-011
Thursday, 26 Oct 2017 08:30am EDT 

Oct 26 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours.Heron Therapeutics Inc - ‍Phase 3 studies for HTX-011 ongoing; NDA filing planned for 2018​.Heron Therapeutics - ‍expect to report top-line results from pivotal phase 3 studies in first half of 2018 and file for FDA review in second half of 2018​.  Full Article

BRIEF-Heron Therapeutics Announces Pricing Of Underwritten Public Offering

* HERON THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK